Wechselwirkungen · NeoRecormon
NeoRecormon 500 IU solution for injection in pre-filled syringe NeoRecormon 2 000 IU solution for injection in pre-filled syringe NeoRecormon 3 000 IU solution for injection in pre-filled syringe NeoRecormon 4 000 IU solution for injection in pre-filled syringe NeoRecormon 5 000 IU solution for injection in pre-filled syringe NeoRecormon 6 000 IU solution for injection in pre-filled syringe NeoRecormon 10 000 IU solution for injection in pre-filled syringe NeoRecormon 20 000 IU solution for injection in pre-filled syringe NeoRecormon 30 000 IU solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 10
HOS-086020 · Präparat HOS-083248
The clinical results obtained so far do not indicate any interaction of NeoRecormon with other medicinal products. Animal experiments revealed that epoetin beta does not increase the myelotoxicity of cytostatic medicinal products like etoposide, cisplatin, cyclophosphamide, and fluorouracil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): etoposide (HOS-086021) cisplatin (HOS-086022) cyclophosphamide (HOS-084539) fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T10:00:00Z · SHA-256 d4885cc4a4f4b8eee4e66452aecdcfd9e0cb2d83ca77d038cff33e2a87f9cdac · Passage 8c4cdfc4bcbcee1553c37a459d723874823cf17c3134a1ed517f91d6f97ebbcb · Zeichen 0–292 im Abschnitt